Mercaptopurine
3 NDCs across 2 manufacturers|3 Generic,0 Brand
Mercaptopurine is used to treat leukemia, lymphocytic, chronic, b-cell, non-hodgkin lymphoma and precursor cell lymphoblastic leukemia-lymphoma, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Feb 11, 2004. FDA's Orange Book lists 5 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $5 million on Mercaptopurine across 43,000 claims for 10,000 beneficiaries.
Mercaptopurine is available as 3 NDCs from 2 manufacturers (3 generic, 0 brand), with NADAC prices from $0.99 to $1.07 per EA — a 8% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
3G / 0B
Manufacturers
2
competing in market
Price Spread
$0.99 – $1.07
per EA
7d Activity
avg +6.0% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Hikma Pharmaceuticals USA Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Nucleoside Metabolic Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
2 manufacturers producing MERCAPTOPURINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
MERCAPTOPURINE 50 MG TABLET | $1.0714 per EA | +5.99% |
MERCAPTOPURINE 50 MG TABLET | $1.0714 per EA | +5.99% |
MERCAPTOPURINE 50 MG TABLET | $0.9929 per EA | — |
Frequently Asked Questions
What is Mercaptopurine used to treat?
Mercaptopurine is used to treat leukemia, lymphocytic, chronic, b-cell, non-hodgkin lymphoma and precursor cell lymphoblastic leukemia-lymphoma, per the National Library of Medicine's MED-RT classification.
When did Mercaptopurine become available as a generic?
FDA approved the first generic Mercaptopurine (ANDA) on Feb 11, 2004. The Orange Book currently lists 5 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Mercaptopurine?
In 2024, Medicare Part D spent $5 million on Mercaptopurine across 43,000 claims for 10,000 beneficiaries.
How many Mercaptopurine products are on the market?
The Mercaptopurine drug market contains 3 NDCs from 2 manufacturers — 3 generic and 0 brand products.
What is the price range for Mercaptopurine?
NADAC reference prices for Mercaptopurine range from $0.9929 to $1.0714 per EA — a 8% difference between cheapest and most expensive.
Which manufacturers make Mercaptopurine?
2 manufacturers list Mercaptopurine in NADAC. Ranked by number of NDCs, the largest are Hikma Pharmaceuticals USA Inc. (2), Mylan Pharmaceuticals Inc. (1).
How has the price of Mercaptopurine changed recently?
Over the past 7 days, 2 Mercaptopurine NDCs rose and 0 fell, with a market-wide average change of +6.0%.